Despite the high prevalence of age-related cataracts, there are currently no known therapies to delay or prevent their occurrence. Studies in humans and rodent models suggest that estrogen may provide protection against age-related cataracts. The discovery of ocular estrogen receptors (ERs) indicates that estrogen protection may result from direct interactions with its receptors in the eye, instead an indirect consequence from effects on another tissue. Studies in our transgenic mouse model validate the concept that estrogen is beneficial for the eye. These mice express ER⌬3, a dominant-negative form of ER␣ that inhibits ER␣ function. In the ER⌬3 transgenic mice, cortical cataracts spontaneously form in ER⌬3 females after puberty and progress with age. The cataracts initiate in the equatorial region of the lens where the epithelial cells differentiate into elongating fiber cells. Cataract formation can be prevented if the females are ovariectomized before, but not after, sexual maturity. Both male and female ER⌬3 mice develop cataracts after neonatal treatment with the potent estrogen diethylstilbestrol (DES). The incidence of spontaneous and DESinduced cataracts in ER⌬3 mice is 100%, yet these cataracts are absent from the wild-type mice. These data suggest that repression of estrogen action induces cortical cataract formation because estrogen is required to activate the ER⌬3 repressor. Evidence of DES-induced cataracts in the ER⌬3 males as well as the females suggests that estrogen is important in lens physiology in both sexes. The ER⌬3 mice provide a powerful model for assessing the role of estrogen in maintaining the transparency of the lens.
C
urrently there is no known therapy that can delay or prevent age-related cataracts that plague the ever-growing numbers of aging men and women. The incidence of age-related cataracts is higher in women (1) , and their onset coincides with estrogen deficiency that occurs after menopause. Until recently, the eye had not been considered to be an estrogen target tissue; however, recent studies have begun to correlate estrogen status with risk of cataracts (2) (3) (4) . In addition, the estrogen receptor (ER) has been detected in ocular tissues (5, 6,) .
Estrogens acting through the ER modulate transcription of estrogen-responsive genes (7) . The ER is a ligand-dependent transcription factor belonging to the nuclear receptor superfamily (8) . Currently, two subtypes of the ER are known to exist, ER␣ and ER␤. The classic ER, which has been associated for decades with female reproductive responses, is now designated as ER␣. The recently discovered second gene codes for ER␤ (9) . Expression of the ER␣ protein has been detected in the rat and bovine (5) and human (6) retina and in the rat lens ʈ ; ER␤ mRNA has been detected in the rat lens (10) . The presence of these receptors indicates that the eye can respond directly to estrogens or antiestrogens, such as tamoxifen.
Studies in women suggest that estrogens may protect against the development of senile cataracts. The three types of agerelated cataracts: nuclear sclerosis, cortical cataract, and posterior subcapsular opacity, occur in the central, peripheral, and posterior regions of the lens, respectively. The Beaver Dam eye study indicated a modest protective effect of lifetime estrogen exposure on cataract risk (4) . In this study, a later onset of menopause was associated with a decreased risk of cortical cataracts; younger age at menarche (onset of menstruation) was associated with a protective effect regarding nuclear sclerosis; and hormone replacement therapy was associated with a lower prevalence of nuclear cataracts. In the Blue Mountains eye study, current use of hormone replacement therapy in women Ͼ65 years of age was associated with a lower prevalence of cortical cataracts (2) . In addition, an increased prevalence of cortical, nuclear, and posterior subcapsular cataracts with later ages at menarche was detected (2), suggesting that a shorter lifetime exposure to estrogen may influence all types of agerelated cataracts. In a study comparing lens transmittance in women taking hormone replacement therapy (measuring nuclear sclerosis), estrogen also was found to be protective (3) . These data strongly suggest that estrogen may protect the lens against opacities. Furthermore, cataracts occur in women taking the antiestrogen tamoxifen to treat or prevent breast cancer (11, 12) , indicating that inhibiting estrogen action can result in the loss of lens transparency.
Two rodent model systems also demonstrate that estrogen may protect the lens from developing cataracts. In an in vivo model, using ovariectomized rats treated with methylnitrosourea, estrogen treatment diminished the incidence of cortical cataracts induced by the mutagen (10) . In addition, the potency of the estrogens tested influenced the efficacy of inhibiting lens opacities, with the weaker estrogen, estrone, being less effective than 17␤-estradiol. In the other model, using cataracts induced by transforming growth factor-␤ in cultured rat lenses, subcapsular cataracts were reduced when 17␤-estradiol was administered to the rat before lens culture or directly to the culture medium before transforming growth factor-␤ treatment (13, ʈ) . These data provide further evidence that estrogens can protect the lens from developing cataracts.
In this study, a transgenic mouse model is examined that expresses ER⌬3, a natural variant of ER␣ resulting from the in-frame deletion of exon 3 by alternative splicing. The deletion of exon 3 (⌬3) of the human ER␣ was originally detected in the T47D breast cancer cell line (14) . Deletion of exon 3 from the ER␣ results in a receptor protein that is lacking only a portion of the DNA-binding domain, mainly the second zinc finger. Other functional domains for nuclear localization, transactivational domains AF-1 and AF-2, ligand-dependent dimerization, and ligand binding remain intact. In transfected HeLa cells, the human ER⌬3 variant alone did not have the ability to activate transcription of an estrogen-responsive reporter construct (14) .
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However, when ER⌬3 is cotransfected with ER␣, dominantnegative activity of the ER⌬3 receptor is evident by its ability to inhibit ER␣ activation of the same estrogen-responsive reporter. Transfecting a 1:10 ratio of ER␣ to ER⌬3 vectors was required to inhibit Ϸ80% of the wild-type (wt) receptor activity (14) . The actual ratio of ER␣ to ER⌬3 required in an individual cell to suppress ER␣ activity has not been determined.
Transgenic mice expressing the mouse ER⌬3 cDNA were generated to examine the function of the ER⌬3 dominantnegative receptor in vivo. Expression of the ER⌬3 cDNA was directed by the rat osteocalcin promoter, truncated to Ϸ200 bp of 5Ј-flanking sequences, in conjunction with a viral murine enhancer (Harvey murine sarcoma virus long terminal repeat). In the ER⌬3 construct, truncation of the osteocalcin promoter resulted in the loss of tissue-specific expression that is usually limited primarily to bone. Therefore, expression of ER⌬3 transgene is detected in most tissues in both lines of ER⌬3 mice (V.L.D., R.R. Newbold, J.F.C., E.H. Goulding, W. Jefferson, E.M. Eddy, B.C. Bullock, and K.S.K., unpublished data). The only spontaneous phenotype evident in the ER⌬3 mice was cataract formation in the females of one line, line F. The effects of the ER⌬3 repressor on cataract development in the transgenic mice are described below.
Materials and Methods
Animals. All procedures involving the mice were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals with a protocol approved by the National Institute of Environmental Health Sciences Animal Care and Use Committee. All mice were housed with 12 h:12 h light:dark cycles in a temperature-controlled room with NIH 31 chow and water provided ad libitum. The ER⌬3 mice were generated on the FVB͞N background strain as will be described elsewhere (V.L.D., R.R. Newbold, J.F.C., E.H. Goulding, W. Jefferson, E.M. Eddy, B.C. Bullock, and K.S.K., unpublished data). The ER⌬3 and wt FVB͞N littermates were produced in the ER⌬3 colony in the National Institute of Environmental Health Sciences animal facilities. At 3 wk of age, mice were weaned, genotyped by using genomic DNA isolated from tail biopsies (15) , and analyzed by PCR as described (16) . Official designations for lines D and F are FVB͞n-TgN(mER⌬3os)04Eme and FVB͞N-TgN(mER⌬3os)06Eme, respectively.
Treatments. For the diethylstilbestrol (DES) treatments and ovariectomized mice, wt FVB͞N female mice (obtained from the National Cancer Institute Animal Program, Bethesda, MD) were bred with hemizygous ER⌬3 males. The progeny were treated with daily injections of DES (Sigma) dissolved in corn oil at the dose of 2 g per pup per day on days 1-5 after birth. Controls were left untreated. Bilateral ovariectomies (OVXs) were performed on untreated females at either 4 wk or 2 mo of age.
Histological Analysis. The eyes from DES-treated, control (intact), and ovariectomized ER⌬3 (transgenic) and FVB͞N (wt) mice were enucleated and fixed in neutral buffered 10% formalin solution for a minimum of 10 days. Eye size was measured by using a calibrated micrometer on a Zeiss Op Mi-1 stereo dissecting microscope. Eyes were dehydrated through a graded alcohol series and embedded in glycol methacrylate. Sections (5 m) were cut through the pupillary-optic nerve axis and stained with hematoxylin and eosin (H&E).
RNase-Protection Assay. RNA was prepared by using a guanidine isothiocyanate͞CsCl gradient procedure from whole eyes from sexually mature females, both ER⌬3 (lines D and F) and wt mice. The RNase-protection assay was performed as described (16) by using a probe generated from the 3Ј end of the mouse ER␣ cDNA and rabbit ␤-globin sequences (from the vector used to generate the transgenic mice). This probe discriminates between the transcripts for the endogenous ER␣ and ER⌬3 transgene, protecting fragments of 368 nt and 422 nt, respectively. The cyclophilin probe, 103 nt, was used as a control probe to normalize the RNA levels between samples.
Results

Detection of Cataracts in ER⌬3
Females. Two lines of ER⌬3 mice, lines D and F, express the ER⌬3 transgene in a variety of tissues, including the liver, lung, kidney, uterus, mammary gland, spleen, heart, brain, and bone (V.L.D., R.R. Newbold, J.F.C., E.H. Goulding, W. Jefferson, E.M. Eddy, B.C. Bullock, and K.S.K., unpublished data). In line F, 100% of hemizygous females developed lens opacities that were visible by gross inspection Ϸ3 mo of age. As the females age, the opacities became more apparent (Fig. 1 Upper) . Histological analysis of eyes from line F females demonstrated that cataract formation was initiated in the equatorial region of the lens and progressed to the cortex and nucleus with age, whereas the lenses in aging wt females (FVB͞N mice) remained normal (Fig. 2) . In addition, histopathology demonstrated that cortical cataracts appeared by age 2 mo in line F females, before clouding of the lens could be detected by gross ocular examination. In the early stages of cataract formation, degenerative changes in elongating fiber cells in the equatorial region of the lens are evident (Fig. 3) . With age, the cataractous changes become extensive, involving nuclear as well cortical regions of the lens (Fig. 2) . The lenses of the line F ER⌬3 females are characterized by cortical vacuoles, globulin formation, and liquefaction and fragmentation in the equatorial, anterior, and posterior subcapsular cortex, in contrast to the normal pattern of even, closely apposed fibers in the wt females (Fig. 2) . Cataracts were not apparent by gross examination or histological analysis in males in line F or either sex in line D at any age.
Effects of Estrogen on Cataract Development. Endogenous estro-
gens. The presence of cataracts only in transgenic female mice expressing an ER␣ variant suggested that estrogen may play a role in the formation of the cataracts observed in the ER⌬3 mice. To investigate whether estrogen was required for cataract formation, line F ER⌬3 and wt females were ovariectomized to produce estrogen-deficient mice. In sexually mature, line F ER⌬3 females, which had produced estrogens for Ϸ1 mo before ovariectomy (post-OVX, Fig. 4) , cataracts did form, as expected. However, if the ovaries were removed from females before sexual maturity, when physiological production of estrogen is minimal (4 wk of age), the lenses of line F ER⌬3 females remained clear even 7 mo after surgery (pre-OVX, Fig. 4) . Therefore, the 1 mo of exposure to ovarian hormones with post-OVX females was critical for inducing cataracts. Removing the source of estrogen production before sexual maturity in the pre-OVX group protected lens transparency. For the wt females, normal lenses were evident irrespective of hormonal status-i.e., intact and pre-OVX and post-OVX groups (data not shown).
Exogenous estrogens. Because endogenous estrogens were required to induce cataracts in the ER⌬3 females, a potent synthetic estrogen, DES, was administered to neonatal ER⌬3 (lines D and F) and wt littermates (daily from 1 to 5 days of age) to determine whether estrogen treatment before sexual maturity could also cause cataract formation. All of the ER⌬3 males and females, both lines D and F, developed cataracts, indicating that DES, like endogenous estrogens, activated the inhibitory activity of the ER⌬3 repressor. The presence of cataracts in both lines of ER⌬3 mice is important because it verifies that cataract induction is a result of expression and activation of the ER⌬3 inhibitor vs. because of disruption of another gene at the site of transgene insertion. Gross examination of the eyes of DEStreated ER⌬3 mice demonstrated that lens opacities were often localized to the interior of the eye (Fig. 1 Lower Right). Cataracts were clearly evident in preweanlings when the eyes first opened at Ϸ2 wk of age (the eyes were not examined before this age). Histological analysis demonstrated severe nuclear cataracts in both ER⌬3 males and females that often result in hypermature cataracts with lens rupture (Fig. 5, 8 -mo-old mice; Fig. 6 , 2-wk-old mice). No lens abnormalities were evident in wt males or females treated with DES (Fig. 5) .
In addition to cataract induction, neonatal DES treatment resulted in microphthalmia in both sexes of the ER⌬3 mice. Eye size in DES-treated ER⌬3 males and females was typically Ϸ80% of that measured for the treated wt mice (Fig. 7) . The eyes otherwise appeared normal, except for the cataractous lens (see Figs. 1, 5, and 6) . No difference in eye size was observed between untreated ER⌬3 and wt mice (data not shown). Histological evidence of cortical cataracts in ER⌬3 females. Sections of eyes from wt, FVB͞N female at 13 mo of age (WT female) and ER⌬3, line F females at 1 mo, 3.5 mo, and 9 mo of age (ER⌬3 female) are shown at ϫ25 (Upper) and ϫ200 (Lower). The Lower panels magnify the bow region of the lens. Retinal degeneration is evident in both the wt and ER⌬3 mice because the ER⌬3 mice were generated on the FVB͞N background strain, which is homozygous for rd, the retinal degeneration gene (22) . (The sections were H&E stained.)
Detection of Ocular ER⌬3 Transcript. The ER⌬3 transcript was detected by RNase-protection assay in RNA isolated from eyes of both line D and F females (Fig. 8) . ER␣ was also detectable in the eyes of both the ER⌬3 and wt females (Fig. 8) . The levels of ER⌬3 are in excess of ER␣ levels, with the transgene constituting 87% and 92% of the total ER␣ transcripts (ER␣ ϩ ER⌬3 mRNAs) in lines F and D, respectively.
Discussion
Cortical cataracts develop spontaneously in ER⌬3 line F transgenic females and progress with age. Estrogen was required to induce cataracts in the ER⌬3 mice. Estrogen dependency was demonstrated by (i) the absence of cataracts in females that had their ovaries removed before, but not after, reaching sexual maturity (Fig. 4) and (ii) the development of cataracts in both males and females after neonatal treatment with the potent estrogen DES (Figs. 5 and 6 ). (These results are summarized in Table 1 .) The RNase-protection assay data demonstrate that both the native ER␣ and the ER⌬3 transgene are expressed in ocular tissues (Fig. 8) , indicating that the effect of estrogen on cataract development can be modulated directly in the eye.
In the ER⌬3 transgenic mouse model, the postulated mechanism of inducing cortical cataracts is by interfering with estrogen signaling, based on the dominant-negative activity of this receptor. This is consistent with the effects of another estrogen inhibitor because cataracts are a known side effect in women treated with tamoxifen (11, 12) . The reason for the estrogen dependence for cataract formation can be logically linked to the prerequisite for estrogen binding to the receptor to induce dimerization of ER⌬3 with itself, ER␣, or ER␤ by means of the ligand-dependent dimerization domain. The other dimerization domain, which is ligand-independent and the weaker dimerization domain for the ER (17), is lost with the exon 3 deletion. Thereby, in mice expressing the ER⌬3 receptor, estrogen would function as an inhibitor by activating the dominant-negative ER⌬3. Therefore, our data concur with other studies demonstrating that estrogen protects the lens from developing cataracts and that loss of estrogen or inhibition of its actions may be instrumental in increasing the risk of developing age-related cataracts.
In ER⌬3 mice, because DES induced estrogen-dependent cataracts in both lines of ER⌬3 mice and both lines would have random, unique sites of insertion of the transgene, cataract development must be due to ER⌬3 expression and not to disruption of another gene at the site of insertion. In addition, excessive accumulation of transgene product within the lens has been shown to disrupt the lens fiber formation simply because of the levels expressed and not related to the function of the expressed protein (18) . However, because cataracts occur in the ER⌬3 mice only when sufficient levels of estrogen are present, the loss of lens transparency could not be due simply to the overexpression of the ER⌬3 protein. Therefore, these data indicate that functional ER⌬3 repressor causes cataract development in both lines of ER⌬3 mice.
Although both lines of ER⌬3 mice express the ER⌬3 repressor in the eye, only line F females develop cataracts spontaneously. The fact that a potent estrogen, DES, can induce cataracts in the line D mice suggests that insufficient levels of estrogen may be responsible for the lack of spontaneous cataracts in this line. Thereby, line F females may produce higher levels of endogenous estrogens because of differential expression in another tissue. Alternatively, the differential levels of ER⌬3 expression in specific ocular tissues in line D may prevent cataract development unless endogenous estrogen levels are supplemented. The effect of neonatal DES treatment on eye size. Eye size of DES-treated mice (treated with 2 g per mouse s.c. on days 1-5 after birth) is shown as the average diameter of both eyes (after fixation), from both anterior-to-posterior and medial lateral measurements, using a calibrated micrometer. The mice were 12-14 mo old. Values given are mean Ϯ SE. ER⌬3 lines F and D and wt littermates were all DES treated. wt males, n ϭ 10; wt females, n ϭ6; ER⌬3 line F males, n ϭ 5 and females, n ϭ 5; and ER⌬3 line D males, n ϭ 4 and females, n ϭ 10. Significance was assessed by using the unpaired Student's t test (␣ ϭ 0.05). P Ͻ 0.001 for ER⌬3 line F and D males and females compared to wt. Further examinations of these lines are necessary to determine whether either or both of these factors result in the lack of spontaneous cataracts in line D females. The single layer of lens epithelial cells is essential for maintaining the metabolic homeostasis and physiological transparency of the entire lens (19) . Conditions that perturb epithelial cell physiology and differentiation can impact cell survival and result in lens opacification. In ER⌬3 mice, in the presence of estrogen, the cortical cataracts always initiate in the equatorial region of the lens, where the differentiation of the epithelial cells into the denucleated, elongating fiber cells occurs. The initiation of cataracts in this critical region suggests that estrogen may be a strategic regulatory factor in the differentiation process. The ability of the ER⌬3 repressor to induce cataracts in the male mice indicates that estrogen is important to the lens physiology in both sexes.
Induction of nuclear cataracts by neonatal DES treatment indicates that DES activation of ER⌬3 disrupts embryonic lens cell differentiation. Importantly, these effects are grossly different from the well-known effects induced by glucocorticoid administration (20) . Corticosteroid cataracts are mainly delimited to the posterior subcapsular region of the lens, although ultrastructural changes have been noted in lens epithelia from patients undergoing corticosteroid therapy (21) . Thus, the lenticular changes seen in the present study are different from those induced by other steroid hormones and appear to involve early development in the epithelium and differentiating fiber cells. The presentation of microophthalmia after neonatal DES treatment suggests that the ER⌬3 repressor also may alter other relevant factors in eye development.
The ER⌬3 mice were generated on the FVB͞N background strain, which is homozygous for rd, the retinal degeneration gene (22) . Therefore, retinal degeneration is inherent to the strain and not related to ER⌬3 expression. The effects of ER⌬3 expression on cataract development in a background strain without the Ϫrd͞Ϫrd genotype require further examination. However, because cataracts developed in neonatal mice before retinal degeneration, retinal degeneration is not expected to contribute to ER⌬3-induced cataract development.
Estrogen influences diverse tissues, including the cardiovascular system, bone, and brain, in addition to having its effects on reproduction. Many age-related diseases that occur in menopausal women are linked to estrogen deficiency and benefit from estrogen therapy. The studies in women and rodent models, including the ER⌬3 model, support the concept that estrogen also may help preserve the transparency of the lens. Future investigations with this model should help uncover the role of estrogen in the lens pathophysiology and its potential as a therapy to delay or prevent age-related cataracts.
